Loading...
FROM EVIDENCE TO PRACTICE: AN EVIDENCE-BASED UPDATE OF THE QATAR NATIONAL CLINICAL GUIDELINES FOR THE ASSESSMENT AND MANAGEMENT OF COMMON ANAEMIAS IN ADULTS
Citations
Altmetric:
Video URL
Date
2026-06
Author
Collections
Files
Ghadeer Murad_OGS Approved Project.pdf
Adobe PDF, 290.32 KB
- Embargoed until 2028-07-01
Abstract
Background: Anaemia is a leading cause of preventable morbidity worldwide, affecting an estimated 1.9 billion people globally(1). The MoPH National Clinical Guideline for the Assessment and Management of Common Anaemias in Adults had not undergone a systematic update since June 2020, and major international organizations including NICE had issued significantly updated guidance across several anaemia subtypes. Aim: To conduct a systematic, evidence-based update of the second draft of the MoPH NCG on Common Anaemias in Adults, incorporating published evidence from 2020 to January 2026, in accordance with the MoPH NCG update methodology. Methods: A structured, section by section review was undertaken across all 26 sections of the existing guidelines. Literature searches were performed in PubMed using condition specific MeSH search strings, supplemented by review of guidelines from nine international organizations. Evidence was appraised for utility, and relevance, and graded using the MoPH framework (Levels 1-3; Recommendation Grades A-C and R-GDG). Amendments were applied as tracked changes for GDG review prior to finalization. Results: Of the 26 sections reviewed, 14 had tracked changes applied and 11 required no change. Twenty-three new or replacement references were incorporated. Major updates included revised WHO haemoglobin thresholds, mandatory serum ferritin in the IDA investigation pathway, intravenous iron in pregnancy, hydroxycarbamide as first line therapy in sickle cell disease, triple immunosuppression for aplastic anaemia, revised haemoglobin targets in anaemia of chronic disease, differentiated AIHA management, and NICE NG239 as the governing source for B12 and folate recommendations. Two critical patient safety notices were issued, including the mandatory removal of voxelotor. Conclusion: The update confirmed that more than half of the guideline's clinical sections required revision, reflecting the pace of evidence evolution in haematology. The most impactful changes addressed sickle cell disease management, aplastic anaemia treatment, and the IDA investigation pathway. The structured NCG update process provided an effective framework for incorporating new evidence and identifying patient safety risks, and the updated guideline now reflects international standards as of January 2026.